CRMD - Why CorMedix Stock Popped Wednesday | Benzinga
CorMedix Inc. (NASDAQ: CRMD) shares traded higher Wednesday after the company reported better-than-expected third-quarter earnings results. Also, the company received Food and Drug Administration approval for DefenCath under NDA: 214520.
What To Know: CorMedix reported its third-quarter earnings results on Nov. 14 after the close of the market. The company posted quarterly losses of 17 cents per share, which topped analyst expectations of losses of 21 cents per share, unchanged from the same period last year.
On Wednesday, CorMedix announced FDA approval of DefenCath, used to lower the incidence of catheter-related bloodstream infections (CRBSIs) for the limited ...